The fact that Muparfostat (PI-88), known to inhibit endo-beta-D-glucuronidase heparanase, has progressed to Phase III clinical trial for hepatocellular cancer, with other efforts also being channeled towards developing small molecule inhibitors and neutralizing antibodies of GAGs as anticancer therapy [141], is ample evidence that GAGS have potential usage in the clinical setting. The gene discussed is HPSE; the disease is hepatocellular carcinoma.